# A Multicenter Expanded Access Treatment Protocol of Lurbinectedin in Previously Treated SCLC in the USA

> **NCT04291937** · — · APPROVED_FOR_MARKETING · sponsor: **Jazz Pharmaceuticals**

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DRUG:** Lurbinectedin

## Key facts

- **NCT ID:** NCT04291937
- **Lead sponsor:** Jazz Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** APPROVED_FOR_MARKETING
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2020-06-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04291937

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04291937, "A Multicenter Expanded Access Treatment Protocol of Lurbinectedin in Previously Treated SCLC in the USA". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04291937. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*